# Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer

> **NCT06152523** · PHASE2 · WITHDRAWN · sponsor: **Assistance Publique - Hôpitaux de Paris**

## Conditions studied

- MSI
- dMMR Colorectal Cancer

## Interventions

- **DRUG:** Monalizumab/MEDI5257

## Key facts

- **NCT ID:** NCT06152523
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-12
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study has been halted because the manufacturer can no longer supply the experimental treatment
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06152523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06152523, "Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06152523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*